Ticker: NASDAQ: ABOS
Founded: 2012
Headquarters: Carmel, Indiana, USA
CEO: Daniel O. Jacobs
Status: Public (acquired by Eli Lilly in 2022)
Market Cap: ~$200 million (2026)
Website: acumenpharma.com
Acumen Pharmaceuticals is a US biotechnology company focused on developing antibodies targeting toxic amyloid-beta (Aβ) oligomers for the treatment of Alzheimer's disease. The company's oligomer-targeting approach addresses what is believed to be the most pathogenic form of amyloid in Alzheimer's disease[1].
Founded in 2012 and headquartered in Carmel, Indiana, Acumen represents a differentiated approach in the crowded Alzheimer's disease therapeutic landscape. While many companies have focused on clearing amyloid plaques, Acumen's platform specifically targets soluble toxic Aβ oligomers—believed by many researchers to be the primary drivers of synaptic dysfunction and cognitive decline in Alzheimer's disease.
In 2022, Acumen Pharmaceuticals was acquired by Eli Lilly and Company for approximately $500 million, bringing together Acumen's innovative oligomer-targeting platform with Lilly's global development and commercial capabilities.
Acumen Pharmaceuticals was founded with a singular scientific vision: to develop therapeutics that specifically target the most toxic forms of amyloid-beta while sparing less harmful species. The company's founding was based on research demonstrating that soluble Aβ oligomers, rather than insoluble plaques, correlate most strongly with cognitive impairment in Alzheimer's disease.
The company's name reflects its scientific approach—acumen meaning "sharpness of mind" and insight, reflecting the goal of preserving cognitive function in patients.
Carmel, Indiana, is part of the Indianapolis metropolitan area, a growing biotechnology hub in the Midwest. The location provides access to:
In 2022, Eli Lilly acquired Acumen Pharmaceuticals for approximately $500 million, integrating Acumen's oligomer-targeting programs into Lilly's neuroscience pipeline. The acquisition validated Acumen's approach and provided significant resources for clinical development.
| Event | Year | Details |
|---|---|---|
| Series A | 2012 | Initial funding to establish platform |
| Series B | 2015 | Pipeline development and IND-enabling studies |
| Strategic Partnership | 2019 | Collaboration with Eli Lilly |
| Acquisition | 2022 | Acquired by Eli Lilly for $500 million |
Acumen's therapeutic approach is grounded in the oligomer hypothesis of Alzheimer's disease pathogenesis. Research over the past two decades has increasingly supported the view that soluble Aβ oligomers are the most synaptotoxic species in Alzheimer's disease[1:1]:
Acumen's proprietary platform enables the development of antibodies that selectively bind to toxic Aβ oligomers while minimizing binding to:
This selectivity is crucial because:
AC-196 is a next-generation monoclonal antibody targeting Aβ oligomers and represents Acumen's lead clinical candidate:
AC-196's clinical program focuses on:
AC-111 was Acumen's first-generation anti-Aβ oligomer antibody:
AC-111 established human proof-of-concept for the oligomer-targeting approach, showing that:
Following the Eli Lilly acquisition, additional programs are being developed:
Acumen's oligomer-targeting approach differentiates it from other Alzheimer's antibody programs:
| Company | Drug | Target | Status |
|---|---|---|---|
| Eisai/Biogen | Leqembi (lecanemab) | Aβ plaques | Approved |
| Biogen | Aduhelm (aducanumab) | Aβ plaques | Approved (withdrawn) |
| Eli Lilly/Acumen | Donanemab | Aβ plaques | Approved |
| Eli Lilly/Acumen | AC-196 | Aβ oligomers | Phase 1 |
Acumen's clinical development is now conducted through its partnership with Eli Lilly, one of the world's leading neuroscience pharmaceutical companies. This provides:
Acumen Pharmaceuticals / Eli Lilly. Company Overview. ↩︎ ↩︎